Latest Biotech News

A Nature paper showed RFdiffusion and allied hypermutation systems can design de novo single‑domain antibodies that bind user‑specified epitopes with atomically accurate poses, and structural work...

Hepta Bio, a startup founded by former Illumina and Grail scientists, closed a $6.7 million seed round to develop transformer‑based AI that interprets cell‑free DNA methylation for chronic disease...

Ginkgo Bioworks secured a Biopharmaceutical Manufacturing Preparedness Consortium contract through BARDA worth up to $22.2 million to develop cost‑reducing, scalable manufacturing approaches for...

Johnson & Johnson’s Caplyta gained FDA approval as an adjunctive treatment for major depressive disorder, expanding the label after J&J acquired the asset via its Intra‑Cellular Therapies...

Researchers reported that inhibiting PIM3 kinase reverses CAR‑T cell dysfunction induced by hypoxia within solid tumor microenvironments, restoring cytotoxic activity in preclinical models. The...

AmacaThera signed a licensing and collaboration agreement with Pacira BioSciences worth up to $230 million for AMT‑143, a hydrogel‑based long‑acting ropivacaine designed for extended...

A Phase I study of an adjuvanted, intranasal recombinant influenza A/H5 vaccine demonstrated broad priming of immune responses across multiple H5 clades, suggesting a mucosal route could provide...

Researchers have demonstrated de novo antibody design with atomic-level accuracy using RFdiffusion and an integrated hypermutation system, validating binding poses by cryo-electron microscopy. The...

The U.S. Food and Drug Administration issued a complete response letter rejecting Biohaven’s New Drug Application for troriluzole in spinocerebellar ataxia, citing concerns about real‑world...

Federal Trade Commission staff warned that Novo Nordisk’s proposed deal structure for a takeover of obesity biotech Metsera may violate the Hart‑Scott‑Rodino premerger review process, raising...

Eli Lilly said its experimental amylin receptor agonist eloralintide met predefined efficacy thresholds and will advance into Phase 3 testing after phase 2 results showing up to 20.1% weight loss...

Hepta Bio, founded by veterans of Illumina and Grail, closed a $6.7 million seed round led by Felicis Ventures and Illumina Ventures to commercialize a transformer‑based AI that reads the...

Researchers unveiled CRISPR PRO‑LiveFISH, a multiplexed live‑cell imaging approach that visualizes chromatin dynamics and promoter–enhancer interactions at multiple non‑repetitive loci. Published...

China’s Ministry of Commerce announced it will lift the export ban on Illumina sequencing systems on November 10, reversing restrictions imposed earlier this year and reopening a critical market...

The FDA approved UCB’s KYGEVVI (combination of pyrimidine nucleosides) as the first treatment for thymidine kinase 2 deficiency (TK2d), an ultra‑rare, often fatal mitochondrial myopathy. Approval...

Ginkgo Bioworks was awarded a BARDA contract worth up to $22.2 million under the BioMaP‑Consortium to develop cost‑reducing, scalable domestic manufacturing for monoclonal antibodies against...

Lonza executives outlined a roadmap to scale CAR‑T and specialized cell therapies through automation, global manufacturing networks, and early bioprocess development. Thomas Fellner, Lonza’s head...

The Federal Trade Commission told Novo Nordisk and Metsera in a formal letter that the structure of Novo’s proposed buyout — an upfront payment for half the company followed by later consideration...

Metsera’s board declared Novo Nordisk’s improved proposal a superior company proposal after a sequence of competing offers from Pfizer and Novo. Novo’s latest package increases upfront dividends...

The FDA issued a complete response letter for Biohaven’s troriluzole New Drug Application for spinocerebellar ataxia, citing methodological issues with the company’s reliance on external control...